title: Thalidomide in relapsed or refractory multiple myeloma: how much and for how long?
abstract: The optimum dose and duration of treatment with thalidomide for relapsed or refractory multiple myeloma are not known. Long term responses were seen in 5 patients given low doses of thalidomide (100-200 mg) with or without pulsed dexamethasone, for between 48 and 108 weeks. The responses were sustained for between 23 and 67 weeks after stopping treatment. We recommend that the lowest effective dose (LED) and optimum duration of therapy with thalidomide should be determined within the framework of a well conducted clinical trial in order to answer these important questions.
authors.affiliation: Imperial College Faculty of Medicine, St Mary's Campus, Norfolk Place London W2 1PG, UK. s.abdalla@ic.ac.uk
authors.forename: Saad Habib
authors.initials: SH
authors.lastname: Abdalla
authors.forename: Sarah
authors.initials: S
authors.lastname: Mahmoud
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003907:Dexamethasone / Q000627:therapeutic use; D016903:Drug Monitoring; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D013792:Thalidomide / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; D003907:Dexamethasone